[
  {
    "ts": "2025-12-09T12:44:00+00:00",
    "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard",
    "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-124400507.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "a24b35c3-6721-3340-9f7a-946ee6134af4",
      "content": {
        "id": "a24b35c3-6721-3340-9f7a-946ee6134af4",
        "contentType": "STORY",
        "title": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard",
        "pubDate": "2025-12-09T12:44:00Z",
        "displayTime": "2025-12-09T12:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-124400507.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-124400507.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T14:21:00+00:00",
    "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
    "summary": "Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up1 Combination regimen granted Breakthrough Therapy Designation by U.S. FDA BEERSE, BELGIUM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI®▼ (teclistamab) plus DARZAL",
    "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-142100255.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7f2ae850-3068-35ba-a447-7ff752b2e00d",
      "content": {
        "id": "7f2ae850-3068-35ba-a447-7ff752b2e00d",
        "contentType": "STORY",
        "title": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
        "description": "",
        "summary": "Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up1 Combination regimen granted Breakthrough Therapy Designation by U.S. FDA BEERSE, BELGIUM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI®▼ (teclistamab) plus DARZAL",
        "pubDate": "2025-12-09T14:21:00Z",
        "displayTime": "2025-12-09T14:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3",
          "originalWidth": 2690,
          "originalHeight": 510,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFgHjEGtPkqKstjJ7xH84w--~B/aD01MTA7dz0yNjkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 2690,
              "height": 510,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m.9C60wTcxkvOQOLX1h8uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-142100255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/unprecedented-results-phase-3-majestec-142100255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T15:18:53+00:00",
    "headline": "The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026",
    "summary": "Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.",
    "url": "https://247wallst.com/investing/2025/12/09/the-5-best-sp-500-dividend-aristocrat-stocks-to-buy-before-2026/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e72fb8a2-41a6-31a1-a7b4-b9e0342343c8",
      "content": {
        "id": "e72fb8a2-41a6-31a1-a7b4-b9e0342343c8",
        "contentType": "STORY",
        "title": "The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026",
        "description": "",
        "summary": "Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.",
        "pubDate": "2025-12-09T15:18:53Z",
        "displayTime": "2025-12-09T15:18:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/134eb3c44c651551e7cbd1d45520e262",
          "originalWidth": 1500,
          "originalHeight": 1000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9N4_fAI86FeZ1AT2EKYAPw--~B/aD0xMDAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/134eb3c44c651551e7cbd1d45520e262.cf.webp",
              "width": 1500,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vHH6DEO1nWa1MpS9I6CmVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/134eb3c44c651551e7cbd1d45520e262.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/09/the-5-best-sp-500-dividend-aristocrat-stocks-to-buy-before-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-best-p-500-dividend-151853334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XOM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ED"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "PEP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T15:09:57+00:00",
    "headline": "Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma",
    "summary": "Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Te",
    "url": "https://finance.yahoo.com/news/johnson-johnson-says-tecvayli-darzalex-150957631.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "93c52f61-2256-3936-90d2-5799a5673757",
      "content": {
        "id": "93c52f61-2256-3936-90d2-5799a5673757",
        "contentType": "STORY",
        "title": "Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Te",
        "pubDate": "2025-12-09T15:09:57Z",
        "displayTime": "2025-12-09T15:09:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-says-tecvayli-darzalex-150957631.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-says-tecvayli-darzalex-150957631.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T09:46:37+00:00",
    "headline": "Stock Market Today: S&P 500, Nasdaq Open Narrowly Lower As Final Fed Meeting of 2025 Kicks Off",
    "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Dec. 9, 2025. You can follow the latest updates on the market ...",
    "url": "https://www.thestreet.com/latest-news/stock-market-today-longtime-tech-bull-downgrades-mag7-tech-giants-in-surprising-pivot",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "a5a7c2bb-1768-3c33-876f-c0e4ff9ff927",
      "content": {
        "id": "a5a7c2bb-1768-3c33-876f-c0e4ff9ff927",
        "contentType": "STORY",
        "title": "Stock Market Today: S&P 500, Nasdaq Open Narrowly Lower As Final Fed Meeting of 2025 Kicks Off",
        "description": "",
        "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Dec. 9, 2025. You can follow the latest updates on the market ...",
        "pubDate": "2025-12-09T09:46:37Z",
        "displayTime": "2025-12-09T09:46:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/2dffc2bf04cdc84c14a9b7de327010dc",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MkuVxIgtnaeQ1ggwUoGOeg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/2dffc2bf04cdc84c14a9b7de327010dc.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DA0DsO8g9R1VX5B9INRiYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/2dffc2bf04cdc84c14a9b7de327010dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/latest-news/stock-market-today-longtime-tech-bull-downgrades-mag7-tech-giants-in-surprising-pivot",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-p-500-094637366.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T16:15:17+00:00",
    "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
    "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
    "url": "https://www.fool.com/investing/2025/12/09/major-factor-behind-healthcare-sector-surge/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "8e41252a-f385-3e6d-b6fc-160f1600eb5c",
      "content": {
        "id": "8e41252a-f385-3e6d-b6fc-160f1600eb5c",
        "contentType": "STORY",
        "title": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
        "description": "",
        "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
        "pubDate": "2025-12-09T16:15:17Z",
        "displayTime": "2025-12-09T16:15:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b8359b35903969793fe847bd47544f1e",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A pharmacist filling a prescription.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n4WsYvsKT0i6iKvYMKBIrQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b8359b35903969793fe847bd47544f1e.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/01.fpwG2i3pPWL2a70mZSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b8359b35903969793fe847bd47544f1e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/09/major-factor-behind-healthcare-sector-surge/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-major-factor-behind-healthcare-161517217.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T18:40:00+00:00",
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finance.yahoo.com/news/pharma-etfs-gain-landmark-uk-184000568.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "54b8e31f-7106-3389-a0ea-83dd20a5c770",
      "content": {
        "id": "54b8e31f-7106-3389-a0ea-83dd20a5c770",
        "contentType": "STORY",
        "title": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
        "description": "",
        "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
        "pubDate": "2025-12-09T18:40:00Z",
        "displayTime": "2025-12-09T18:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/2126bb4561121cb77df48d177ed4717c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qd4eVm2MYMmt24ScYmbvqQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2126bb4561121cb77df48d177ed4717c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o7_YiS6tbohgvl_i9e24ew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2126bb4561121cb77df48d177ed4717c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-gain-landmark-uk-184000568.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-gain-landmark-uk-184000568.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "PJP"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]